Drug intelligence / Profile preview

pneumostem

Development stage: Phase 2
Lead developer: Medipost
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intratracheal

Overview

Pneumostem is an allogeneic cell therapy consisting of ex vivo cultured, unrelated, human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs). Developed by the South Korean biotechnology company MEDIPOST, it is intended for the prevention and treatment of bronchopulmonary dysplasia (BPD) in premature infants. The therapy is administered via a single intratracheal dose and aims to leverage the anti-inflammatory and regenerative properties of mesenchymal stem cells to mitigate lung injury and promote tissue repair in neonates at high risk for chronic lung disease.

Brand names: Pneumostem
Other names: human umbilical cord blood-derived mesenchymal stem cellshUCB-MSCs

Beyond the preview

Go deeper on pneumostem.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pneumostem.

Explore the full profile